Table 1.
Characteristics of the included studies.
| Author, Year | Radiotracer Dose | Time Interval between Injection and Scanning | PSA | Standard of Truth | # Patients |
|---|---|---|---|---|---|
| Baratto, 2021 [19] | 270.1 to 366.3 MBq (333 ± 25.9 MBq) | 60 to 120 min (81.2 ± 17 min) | Mean 5 ng/mL | At least part of the data was validated by histopathology | 28 |
| Chaussé, 2021 [20] | 9 ± 1 mCi (333 ± 37 MBq) | 60–90 min | Median 2.27 ng/mL | At least part of the data was validated by histopathology | 93 |
| Koschel, 2021 [21] | 250 MBq ± 50 MBq | 120 min | Median 0.32 ng/mL | No histopathologic validation | 98 |
| Luiting, 2021 [22] | Not provided | Not provided | Median 0.30 ng/mL (IQR 0.23–0.70) | No histopathologic validation | 157 |
| Markowski, 2020 [15] | 333 MBq (9 mCi) | 60 min | Median 0.7 ng/mL (IQR 0.3–1.8) | No histopathologic validation | 108 |
| Meijer, 2021 [23] | 311 MBq (interquartile range (IQR) 301–322 MBq) | 120 min | The median PSA level at the time of the PET scan post-RARP was 0.5 ng/mL (IQR 0.2–1.1), median 0.9 ng/mL (IQR 0.3–2.8) in patients post-RARP + SRT, and median 2.8 ng/mL (IQR 1.3–5.6) in patients post-EBRT | No histopathologic validation | 253 |
| Mena, 2020 [18] | Mean 299.9 ± 15.5 MBq, 8.09 mCi (6.2–8.8 mCi) | - | Median 2.5 ng/mL (range 0.21–35.5) | At least part of the data was validated by histopathology | 90 |
| Mena, 2022 [12] | Mean 296 ± 33.3 MBq [8.0 ± 0.9 mCi]; range, 207.2–325.6 MBq (5.6–8.8 mCi) | 1–2 h | Median 1.6 ng/mL (range, 0.2–35.5) | No histopathologic validation | 245 |
| Metser, 2021 [24] | 327 (±16.7) | 110.2 (±13.9) min | Median 3.0 mg/mL (range 0.5–43.3) | At least part of the data was validated by histopathology | 35 |
| Morris, 2021 [11] | MBq median 349 range (277–410), mCi 9.42 (7.49–11.07) | median 79 range (59–115) | Median 0.8 ng/mL | At least part of the data was validated by histopathology | 208 |
| Ortega, 2020 [25] | 335.5 MBq (range, 223–376 MBq) | approximately 120 min (mean, 115.1 min; range, 83–168 min) | Median 3.69 mg/L (range, 0.55–49.9 mg/L) | No histopathologic validation | 142 |
| Perry, 2021 [26] | 250 MBq (±50 MBq | 120 min (±10 min) | Median 0.51 ng/mL (range, 0.08–58.9) | No histopathologic validation | 222 |
| Rousseau, 2019 [27] | The administered activity was scaled by body weight (range, 237–474 MBq), allowing a 10% variation in target activity. | 120 min | Mean ± SD 5.20 ng/mL ± 6.50 | No histopathologic validation | 130 |
| Rowe, 2020 [28] | 333 MBq (9 mCi) | 60 min | Median 0.4 ng/mL (range, 0.2–28.3) | No histopathologic validation | 31 |
| Song, 2019 [16] | Mean 338.8 ± 25.3 | 60 min | Median 3.0 ng/mL (range, 0.23 to 698.4 ng/mL) | At least part of the data was validated by histopathology | 72 |
| Ulaner, 2022 [13] | 333 MBq (9 mCi) ± 10% | 60 min | Median 0.7 ng/mL (range, 0.2–38.9 | All data was validated by histopathology | 92 |
| Wondergem, 2019 [29] | 311 MBq | 120 min | _ | No histopathologic validation | 248 |
Abbreviations, IQR: interquartile range, RARP: robot-assisted radical prostatectomy, SRT: salvage radiotherapy.